BIONET Corp. (TPEX:1784)

Market Cap	3.65B +4.6%
Revenue (ttm)	1.24B +1.2%
Net Income	51.43M -38.6%
EPS	1.02 -38.2%
Shares Out	50.31M
PE Ratio	71.18
Forward PE	n/a
Dividend	1.42 (1.95%)
Ex-Dividend Date	Oct 1, 2026

Volume	168,891
Average Volume	193,160
Open	71.90
Previous Close	71.90
Day's Range	71.10 - 73.20
52-Week Range	63.40 - 118.00
Beta	0.56
RSI	31.53
Earnings Date	May 12, 2026

About BIONET

BIONET Corp. engages in the cell therapy business in Taiwan and internationally. The company offers stem cell banking services, such as stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and PBSC and immune cells; and genetic testing services. It also provides storage and application of hematopoietic stem cells; regenerative medicine, analytical testing, clinical and preclinical research, and commercialized cell-derived products; and Exosome, a cell-free therapy. The company was founded in 1989 and is...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1989
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 1784

Financial Performance

In 2025, BIONET's revenue was 1.24 billion, an increase of 1.19% compared to the previous year's 1.22 billion. Earnings were 51.43 million, a decrease of -38.56%.